Sale
Massive Discounts! Up to 30% OFF on reports🎉

Krabbe Disease Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Krabbe Disease Treatment Market is Segmented By Disease Type (Infantile, Late-onset), By Diagnosis (Laboratory tests, Imaging tests, Genetic testing, Newborn screening, Others), By Treatment (Anticonvulsant Agents, Muscle Relaxer Drugs, Bone Marrow Transplantation, Stem cell transplantation, Others), By End-User (Hospitals, Diagnostic Centers, Clinics, Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published: February 2025 || SKU: PH5230
excelpdfpowerpoint
180 pages
Report Summary
Table of Contents
List of Tables & Figures
Download Free Sample

Market Overview

Krabbe Disease Treatment Market is growing at a high CAGR 7.86% during the forecast period (2024-2031).

Krabbe disease is a life-threatening neurological disorder commonly known as globoid cell leukodystrophy. It is one of a series of conditions known as leukodystrophies, caused by the breakdown of myelin in the nervous system (demyelination). Myelin is the protective layer that surrounds nerve cells and ensures that nerve signals are transmitted quickly. Krabbe illness is also characterized by aberrant brain cells known as globoid cells, huge cells with more than one nucleus. Krabbe disease is identified in children as young as six years old, and there is presently no cure; nevertheless, the condition is controlled by supportive care.

As per DataM Intelligence, Krabbe Disease Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Krabbe Disease Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Krabbe Disease Treatment Market in the United States and Canada produces the utmost share. Whereas the European Krabbe Disease Treatment Market is projected to continue its presence globally during the period of 2022- 2029.

Krabbe Disease Treatment Market Dynamics

Advancement in the therapies for the treatment of Krabbe Disease is expected to drive market growth.

Other experimental medicines have demonstrated varying degrees of effectiveness in preclinical testing, with some of the best results from combining medications. For instance, HSCT has been used with SRT and gene therapy. The combinations consistently yield better outcomes than the matched individual therapies. Other approaches such as ERT, chaperone therapy, and anti-inflammatory therapy also have the potential to contribute as part of a combination or standalone therapies. Moreover, various clinical studies have been carried out. For instance, D-Cycloserine is an FDA-approved medicine for tuberculosis tested in numerous clinical studies for various diseases. Preliminary data suggest that it can slow disease progression in twitcher mice; consequently, D-cycloserine should be studied further to see if it can help individuals with Krabbe disease. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

The finite patient pool for clinical trials, lack of awareness of the disease and side effects of the drugs are factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The risk of severe forms of COVID-19 may be high in the rare metabolic community, where all patients, including children, experience multiorgan impairments due to their chronic condition. MetabERN, the European Reference Network for Hereditary Metabolic Diseases, conducted two surveys: one for patients' organizations (PO) and the other for healthcare providers (HCPs). COVID-19 incidence was lower in the community of uncommon metabolic patients (72.9 per 100,000 vs. 117 per 100,000) than in the general European population. On the other hand, patients were subjected to significant disruptions in their care, with most appointments and treatments being canceled, curtailed, or postponed. Almost all HCPs (90 percent) used telemedicine to replace face-to-face visits, about half of patients undergoing treatment changes switched from hospital to home therapy, and a quarter of patients had difficulty getting their medications.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Market Segment Analysis

Stem cell transplantation segment is expected to hold the largest market share in krabbe disease treatment market

The stem cell transplantation segment is expected to dominate in 2021. The segment benefits because if treatment begins before the development of symptoms, that is, when a diagnosis is made via a newborn screening test, this therapy may improve outcomes in newborns. According to current evidence, stem cell transplantation is most beneficial when initiated before a newborn reaches the age of two weeks. Moreover, Pre-symptomatic children who have stem cell transplantation had a slower disease progression and a better quality — and duration — of life than children who do not receive stem cell transplantation before symptoms arise, according to studies. Furthermore, This medication may also benefit older children and adults with modest Krabbe disease symptoms. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Krabbe Disease Treatment Market

MetricsDetails
Market CAGR7.86%
Segments CoveredBy Disease Type, By Diagnosis, By Treatment, By End-User, By Distribution Channel, and By Region
Report Insights CoveredCompetitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing RegionAsia Pacific
Largest Market Share North America

Market Geographical Analysis

North America region holds the largest market share in the global krabbe disease treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of Krabbe Disease, rising geriatric population, Rapid adoption of cutting-edge technologies and novel medications for the treatment of Krabbe illness, well-established infrastructure and increase in clinical development of the treatment for the Krabbe disease, and rise in investment in research & development are some of the factors the market is expected to boost in the forecast period. For instance, the Krabbe disease affects about 1 in 100,000 people in the United States. It is also known as globoid cell leukodystrophy. Males are affected as often as females.

Also, more than two-fifths of all known cases of Krabbe disease is caused by a missense mutation in the GLC enzyme. Therapeutic approaches for other lysosomal storage diseases are ineffective in treating Krabbe disease due to the lack of accumulated primary substrate within the lysosome and the predominant CNS sickness. The molecules are being researched because they have the potential to pass the blood-brain barrier more efficiently than enzymes due to certain properties such as low molecular weight, low toxicity, and high bioavailability. Allosteric chaperones, directed away from the enzyme's active site, have also been found. Pharmacological chaperone therapy, which is expected to be effective, can be used to treat Krabbe disease. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Key Development

For instance in March 2024, Forge Biologics, announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), granted Innovation Passport designation to the Company’s novel AAV gene therapy program, FBX-101, thus entering the Innovative Licensing and Access Pathway (ILAP). Eventually accelerating regulatory and market access interactions in the UK

Market Competitive Landscape

Major key players in the krabbe disease treatment market are Lannett, Novartis, Lundbeck, Lupin Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Meda Pharmaceuticals Inc   , Mayne Pharma Group Limited, Pfizer Inc., Schwarz Pharma, Inc, Acorda Therapeutics Inc.         

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

­Product Portfolio:

SKELAXIN(metaxalone): Metaxalone is a muscle relaxant. It works by blocking nerve impulses (or pain sensations) in the brain. It is used with rest and physical therapy to treat skeletal muscle conditions such as pain or injury.

Buy this report
Single User
$4350
Multiple User
$4850
Enterprise User
$7850
Proceed to Buy
  Get Free Sample
  Request new version
  Customize Sample
  Demo Full Report
Related Reports
pharmaceuticals iconpharmaceuticals

Crohn’s Disease Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2025 February 13

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Chronic Kidney Disease Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 November 12

Starting from

$5350

pharmaceuticals iconpharmaceuticals

Wilsons Disease Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 August 22

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Neglected Tropical Disease Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 September 12

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Parkinson’s disease Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2025 February 21

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Global Gaucher Disease Treatment Market Size, Share Analysis, Growth Insights and Forecast 2025-2033

Published: 2025 March 06

Starting from

$4350